Avis et décisions de la HAS
La recommandation relative à la prise en charge à titre dérogatoire de l’infliximab (REMICADE) dans le cadre d’une recommandation temporaire d’utilisation, ci-jointe, est adoptée.
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
sJaPCduSZDBGeRre